No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
WFRD Weatherford International
- 110.410
- -3.300-2.90%
Close Apr 17 16:00 ET
- 110.470
- +0.060+0.05%
Post 19:59 ET
7.98BMarket Cap19.51P/E (TTM)
114.920High110.300Low783.84KVolume113.640Open113.710Pre Close87.45MTurnover1.11%Turnover Ratio19.51P/E (Static)72.32MShares127.45052wk High8.64P/B7.83BFloat Cap55.81452wk Low--Dividend TTM70.89MShs Float127.450Historical High--Div YieldTTM4.06%Amplitude1.310Historical Low111.567Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Weatherford International Is Maintained at Strong Buy by Raymond James
Weatherford International Is Maintained at Strong Buy by Raymond James
Weatherford International Plc's (NASDAQ:WFRD) Business Is Trailing The Industry But Its Shares Aren't
When you see that almost half of the companies in the Energy Services industry in the United States have price-to-sales ratios (or "P/S") below 1x, Weatherford International plc (NASDAQ:WFRD) looks to
Express News | Weatherford International PLC : Raymond James Raises Target Price to $152 From $134
Weatherford Releases 2023 Digital Annual Update
HOUSTON, April 16, 2024 (GLOBE NEWSWIRE) -- Weatherford International plc (NASDAQ: WFRD) ("Weatherford" or the "Company") announced the release of its 2023 Annual Update, highlighting outstanding resu
A Glimpse Into The Expert Outlook On Weatherford International Through 4 Analysts
Weatherford International (NASDAQ:WFRD) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The following table encapsulates the
Weatherford International Is Maintained at Buy by B of A Securities
Weatherford International Is Maintained at Buy by B of A Securities
Comments
Weatherford International's rise in ROCE and decrease in capital employed suggest enhanced efficiency in generating returns. The substantial total return over the past three years signals investors' anticipation of more positive future performance.
Why We Like The Returns At Weatherford International (NASDAQ:WFRD)Weatherford International's high P/S ratio isn't justified given its below-industry projected revenue growth. The company's current price levels and not so promising growth outlook warrant investor caution. Future disappointment is possible if P/S falls to match the growth outlook.
$Weatherford International(WFRD.US$ on the way rising
1
Market Summary 15th August
Market Summary 15/8/2023
August kicked off with a noticeable 5% dip in the QQQ. However, a respite was observed, likely due to the $ARK Innovation ETF(ARKK.US$ ETF's continuous downfall in the last nine sessions, leading to a significant 17% drop this month. Such sharp declines are expected after robust growth periods, but it's concerning when they coincide with a trend switch to net lows. Even with today's market uplift, there was a rise in net lows for the Nasdaq an...
August kicked off with a noticeable 5% dip in the QQQ. However, a respite was observed, likely due to the $ARK Innovation ETF(ARKK.US$ ETF's continuous downfall in the last nine sessions, leading to a significant 17% drop this month. Such sharp declines are expected after robust growth periods, but it's concerning when they coincide with a trend switch to net lows. Even with today's market uplift, there was a rise in net lows for the Nasdaq an...
19
2
ColumnsToday's pre-market stock movers: NVAX, DOCU, WDC, CPB and more
Gainers:
• $DBV Technologies(DBVT.US$ +23.5% (positive topline results from Phase 3 EPITOPE Trial)
• $Aldeyra Therapeutics(ALDX.US$ +19.2% (achieves primary endpoint in phase 3 tranquility-2 trial)
• $MediciNova(MNOV.US$ +11.9% (top-line results from phase 2 clinical trial of MN-166)
• $Torrid(CURV.US$ +11% (In reaction to earnings/guidance)
• $Novavax(NVAX.US$ +10.1% (FDA advisory committee recommends EUA for its COVID-19 v...
• $DBV Technologies(DBVT.US$ +23.5% (positive topline results from Phase 3 EPITOPE Trial)
• $Aldeyra Therapeutics(ALDX.US$ +19.2% (achieves primary endpoint in phase 3 tranquility-2 trial)
• $MediciNova(MNOV.US$ +11.9% (top-line results from phase 2 clinical trial of MN-166)
• $Torrid(CURV.US$ +11% (In reaction to earnings/guidance)
• $Novavax(NVAX.US$ +10.1% (FDA advisory committee recommends EUA for its COVID-19 v...
23
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg